APRIL MARIE CALANGI: Open Payments
NPI 1932879301 · PLAYA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$481 in 19 payments from 9 companies in 2025. Trend: 2023 $196 · 2024 $693 · 2025 $481
Food & beverage: $481
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $102 |
| GlaxoSmithKline, LLC. | 4 | $93 |
| ABBVIE INC. | 3 | $81 |
| SHIELD THERAPEUTICS INC | 2 | $58 |
| Novo Nordisk Inc | 2 | $37 |
| Lilly USA, LLC | 1 | $32 |
| Ardelyx, Inc. | 1 | $31 |
| Amgen Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
Products named: Kerendia, ACCRUFER, TRELEGY ELLIPTA, VRAYLAR, SHINGRIX, Ozempic, CREON, ZEPBOUND.
Industry payments across CA — which companies pay providers there.
